hamilton health sciences jobs

Canadian Study Using Cloud DX Technology Proves Remote Patient Monitoring Improves Patient Outcomes

Research using Canadian technology by Cloud DX provides evidence healthcare decision-makers need; RPM improves patient outcomes and healthcare delivery.

News in Summary

  • A recent study called Post Discharge After Surgery Virtual Care with Remote Automated Monitoring Technology-1 (PVC -RAM 1) proves remote patient monitoring (RPM) improves patient outcomes.
  • Results show that virtual care patients saw a 24% reduction in drug errors, up to 14% fewer patients reported pain, and there were 5% fewer re-admissions or emergency room visits.
  • The study comes as Healthcare Units around the world struggle to address COVID-19 related issues. These results spurred adoption of this post-surgical model of care, using Cloud DX's Connected Health™ platform, which is already being broadly adopted in Canada and the United States.

Cloud DX (TSXV:CDX)(OTCQB:CDXFF), A national medical study using Cloud DX's Connected Health™ platform, led by P.J. Devereaux and Michael McGillion of the Population Health Research Institute proves remote patient monitoring (RPM) improves patient outcomes. Results show post-surgical RPM provides greater detection and correction of drug errors, reduces patient pain, and could reduce hospital re-admissions and emergency room visits

"Healthcare can be better. With the recent rapid industry innovation, we are now conclusively seeing improvements in patient results from RPM," says Robert Kaul, CEO and co-founder of Cloud DX. "Anecdotally, we know remote patient care is great and offers more convenience. However, for physicians, administrators and payers there has been a lack of strong evidence proving ROI when deciding what innovations to adopt and implement. Until now."

The study, called "Post discharge after surgery Virtual Care with Remote Automated Monitoring technology-1" (PVC-RAM 1), included over 900 patients at nine hospitals. Scientists sought to evaluate if RPM, when used for 30 days post-surgery, improved patient outcomes compared to standard care (where the onus is on the patient to seek healthcare support). Patients using Cloud DX's Connected Health™ Kit had their vital signs monitored at home: heart rate, blood pressure, oxygen saturation, respiration rate, body temperature, and weight. Patients could also send nurses photos of surgical wounds and virtually access a nurse or doctor 24 hours a day.

Results revealed that virtual care prevented and resolved 24% more medication errors during patient care transitions than the standard care cohort. Patients under virtual care also reported 10-14% less pain. With 5% fewer patients returning to hospital compared to standard care, the study indicated a possibility of reducing re-admissions and emergency visits.

"Remote patient monitoring is convenient, efficient, and effective. There is enormous potential for the broader society," says Devereaux, a senior scientist at Population Health Research Institute (PHRI), a joint institute of McMaster University and Hamilton Health Sciences (HHS). "Something positive that has resulted from COVID is that it has forced healthcare to move more rapidly with remote patient care and RPM. If we can monitor and manage patients virtually, there are upsides for population health as going to a busy clinic or hospital has inherent risk."

"It is about innovating for the future of healthcare. The field is evolving, we need the clinical studies to make the right kind of investments into RPM," says McGillion, a scientist at PHRI. "We need to discover what are the best models are to preserve patient health and safety, optimize healthcare delivery, and improve patient outcomes and healthcare-related costs."

The PVC-RAM-1 study served as the foundation for the new surgical transitions program at HHS and St. Joseph's Healthcare Hamilton. It features a joint command centre to monitor patients remotely as they recover from surgery at home.

Join CEO Robert Kaul in October for an in-depth look at Cloud DX's future roadmap. The company's next monthly investor's update, 'Generating Revenue in RPM' will be held October 12, 2021, at 12:00 pm EDT. Registration is now live

Additional Information

The BMJ today published "Effect of post discharge after surgery virtual care with remote automated monitoring-1 technology versus standard care."

More about the study, PVC-RAM-1

About Cloud DX

Accelerating virtual healthcare's future, Cloud DX is making healthcare better for everyone. The company's Connected Health™ remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable ageing in place, and deliver hospital-quality post-surgical care. Providers partnering with Cloud DX achieve better healthcare and patient outcomes, reduce the need for hospitalization/re-hospitalization, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers."

Cloud DX Investor Sitehttps://ir.clouddx.com/overview/default.aspx

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Social Links

Twitter: https://twitter.com/CloudDX
Facebook https://www.facebook.com/clouddxinc/
LinkedIn https://www.linkedin.com/company/cloud-dx/
Instagram https://www.instagram.com/cloud.dx/

For media inquiries please contact:

Janine Scott
Marketing Lead
888-543-0944
janine.scott@clouddcx.com

For investor inquiries please contact:

Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@CloudDX.com

SOURCE: Cloud DX Inc.



View source version on accesswire.com:
https://www.accesswire.com/667172/Canadian-Study-Using-Cloud-DX-Technology-Proves-Remote-Patient-Monitoring-Improves-Patient-Outcomes

News Provided by ACCESSWIRE via QuoteMedia

The Conversation (0)
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies Inc.  Opens the Market

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
XReality Group

xReality Group Limited Chairman’s Address 2024 Annual General Meeting – 22 November 2024

xReality Group Limited (ASX:XRG) (xReality) is pleased to present xReality Group Limited’s 2024 Annual General Meeting.

Keep reading...Show less
XReality Group

Operator XR – Sales Update November 24

xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following sales update for Operator XR, a wholly owned subsidiary of xReality Group Ltd. Operator XR provides Military and Law Enforcement agencies around the world with a unique, integrated Mission Planning & Rehearsal System, which is portable, secure, and highly immersive.

Keep reading...Show less

Latest Press Releases

Related News

×